urlhttps3A2F2Fwww.usnews.com2Fcmsmedia2F7d2F61749b4d1c6d85cca498f33ac4e0ef2Ftag3Areuters.c

Analysis-More Mega Deals Coming as Chase for Scale Fuels Near Record-Breaking Year for M&A

Ravi Singh2 hours ago06 mins

By Anousha Sakoui, Dawn Kopecki and Kane Wu LONDON/NEW YORK/HONG KONG, Dec 18 (Reuters) – Dealmakers got what they wanted in 2025: an almost record-breaking year ‌for mergers and acquisitions despite a turbulent spring that threatened hopes of a revival ‌in activity during U.S. President Donald Trump’s second term. The chase for scale is fueling…

urlhttps3A2F2Fwww.usnews.com2Fcmsmedia2F522F13980e165b8d845c4b02012bc6e69d2Ftag3Areuters.c

Exclusive-US FDA Taps Merck Drugs With Blockbuster Sales Potential for National Priority Vouchers

Ravi Singh13 hours ago03 mins

By Patrick Wingrove and Dan Levine Dec 17 (Reuters) – The U.S. Food and ‌Drug Administration is moving to fast-track reviews of ‌two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters. Merck’s cholesterol pill enlicitide decanoate and its cancer therapy sacituzumab tirumotecan, or sac-TMT, have been tapped for the Commissioner’s…